A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma
Latest Information Update: 13 Oct 2022
At a glance
- Drugs Manfidokimab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Akeso Biopharma
- 10 Oct 2022 Status changed from not yet recruiting to discontinued.
- 01 Dec 2021 Status changed from planning to not yet recruiting.
- 19 Oct 2021 New trial record